The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.
## Materials

| **Antibodies** | Yes | n/a |
|----------------|-----|-----|
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | | Not available because we used only publicly available data and materials in this study. |

| **Cell materials** | Yes | n/a |
|-------------------|-----|-----|
| **Cell lines:** Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | Not available because we used only publicly available data and materials in this study. |
| **Primary cultures:** Provide species, strain, sex of origin, genetic modification status. | | Not available because we used only publicly available data and materials in this study. |

| **Experimental animals** | Yes | n/a |
|--------------------------|-----|-----|
| **Laboratory animals:** Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | Not available because we used only publicly available data and materials in this study. |
| **Animal observed in or captured from the field:** Provide species, sex and age where possible | | Not available because we used only publicly available data and materials in this study. |
| **Model organisms:** Provide Accession number in repository (where relevant) OR RRID | | Not available because we used only publicly available data and materials in this study. |

| **Plants and microbes** | Yes | n/a |
|-------------------------|-----|-----|
| **Plants:** provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | Not available because we used only publicly available data and materials in this study. |
| **Microbes:** provide species and strain, unique accession number if available, and source | | Not available because we used only publicly available data and materials in this study. |

| **Human research participants** | Yes | n/a |
|-------------------------------|-----|-----|
| Identify authority granting ethics approval(IRB or equivalent committee(s), provide reference number for approval. | | Not available because we used only publicly available data and materials in this study. |
| Provide statement confirming informed consent obtained from study participants. | | Not available because we used only publicly available data and materials in this study. |
| Report on age and sex for all study participants. | | Not available because we used only publicly available data and materials in this study. |
## Design

| Study protocol | Yes (indicate where) | n/a |
|----------------|----------------------|-----|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | Not available because our study is not clinical trials. |

| Laboratory protocol | Yes (indicate where) | n/a |
|---------------------|----------------------|-----|
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | Not available because the protocols are original. |

| Experimental study design (statistics details) | Yes (indicate where) | n/a |
|------------------------------------------------|----------------------|-----|
| State whether and how the following have been done, or if they were not carried out. | | Not available because we used only publicly available data and materials in this study. |
| Sample size determination | | |
| Randomisation | | |
| Blinding | | |
| Inclusion/exclusion criteria | | |

| Sample definition and in-laboratory replication | Yes (indicate where) | n/a |
|-------------------------------------------------|----------------------|-----|
| State number of times the experiment was replicated in laboratory | | |
| State number of times the experiment was replicated in laboratory | | |

| Ethics | Yes (indicate where) | n/a |
|--------|----------------------|-----|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | Not available because we used only publicly available data and materials in this study. |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | Not available because we used only publicly available data and materials in this study. |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | Not available because we used only publicly available data and materials in this study. |

| Dual Use Research of Concern (DURC) | Yes (indicate where) | n/a |
|------------------------------------|----------------------|-----|
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | Not available because we used only publicly available data and materials in this study. |
## Analysis

| Attrition | Yes | n/a |
|-----------|-----|-----|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | | Not available because we didn’t exclude any sample or data from the analysis. |

| Statistics | Yes (indicate where) | n/a |
|------------|----------------------|-----|
| Describe statistical tests used and justify choice of tests. | Section "Methods". | |

| Data Availability | Yes (indicate where) | n/a |
|-------------------|----------------------|-----|
| State whether newly created datasets are available, including protocols for access or restriction on access. | | Not available because we have no newly created datasets. |
| If data are publicly available, provide accession number in repository or DOI or URL. | URL: https://portal.gdc.cancer.gov/ | |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | URL: https://portal.gdc.cancer.gov/ | |

| Code Availability | Yes (indicate where) | n/a |
|-------------------|----------------------|-----|
| For all newly generated code and software essential for replicating the main findings of the study: | | Code is available upon request. |
| State whether the code or software is available. | Software is available in section "Methods". | |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | Code is available upon request. |

## Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---------------------------------|-----------------------------------------------|-----|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | | Not available because we used only publicly available data and materials in this study. |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. | |

Article information: http://dx.doi.org/10.21037/atm-20-922